Tagrisso Archives -

Tagrisso paired with Hutchmed drug clears lung cancer test

Phil Taylor AstraZeneca, HutchMed, Non-small cell lung cancer, Oncology, Orpathys, Tagrisso, targeted oncology 0 Comment

EGFR inhibitors like AstraZeneca’s Tagrisso have been hugely successful in treating EGFR-positive lung cancer, but the durability of

Tagrisso paired with Hutchmed drug clears lung cancer test

https://pharmaphorum.com/news/tagrisso-paired-with-hutchmed-drug-clears-lung-cancer-test/

AstraZeneca plant. AstraZeneca has been working on a vaccine for the Coronavirus, COVID and COVID-19.

News/ News/ Oncology

Scotland is world’s first country to greenlight Tagrisso for NSCLC

Joy Persaud Astra Zeneca, lung cancer, NSCLC, Tagrisso 0 Comment

Scotland has given the green light to AstraZeneca’s Tagrisso for restricted use to treat adult patients with non-small

Scotland is world’s first country to greenlight Tagrisso for NSCLC

https://pharmaphorum.com/news/scotland-is-worlds-first-country-to-greenlight-tagrisso-for-nsclc/

News/ News/ Sales and Marketing

AZ’s COVID-19 jab sales top $1.2bn, but come at a loss

Phil Taylor AstraZeneca, coronavirus, COVID-19, COVID-19 vaccine, Farxiga, Financial, Imfinzi, Lynparza, Tagrisso 0 Comment

AstraZeneca said this morning that it has made $1.2 billion in sales from its COVID-19 vaccine Vaxzevria in

AZ’s COVID-19 jab sales top $1.2bn, but come at a loss

https://pharmaphorum.com/news/azs-covid-19-jab-sales-top-1-2bn-but-come-at-a-loss/

AstraZeneca's (AZ) Tagrisso (osimertinib)

News/ News/ Oncology

Patients in England get fast access to AZ’s Tagrisso in early lung cancer

Richard Staines AstraZeneca, lung cancer, market access, NICE, Tagrisso 0 Comment

The UK’s drugs regulator has swiftly granted a licence extension for AstraZeneca’s Tagrisso in certain patients with early

Patients in England get fast access to AZ’s Tagrisso in early lung cancer

https://pharmaphorum.com/news/patients-in-england-get-fast-access-to-azs-tagrisso-in-early-lung-cancer/

News/ News/ Oncology

AZ’s Tagrisso gets new early lung cancer use in US

Richard Staines AstraZeneca, cancer, lung cancer, Oncology, Tagrisso 0 Comment

AstraZeneca’s Tagrisso (osimertinib) has been approved by the FDA in a new lung cancer indication that extends its

AZ’s Tagrisso gets new early lung cancer use in US

https://pharmaphorum.com/news/azs-tagrisso-gets-new-early-lung-cancer-use-in-us/

Janssen J&J Johnson and Johnson pharmaceutical companies

News/ News/ Oncology

J&J files lung cancer bispecific amivantamab for FDA approval

Phil Taylor amivantamab, AstraZeneca, Janssen, Johnson & Johnson, Non-small cell lung cancer, Tagrisso 0 Comment

Johnson & Johnson has filed its bispecific antibody amivantamab to the FDA, hoping to muscle into the big

J&J files lung cancer bispecific amivantamab for FDA approval

https://pharmaphorum.com/news/jj-files-lung-cancer-bispecific-amivantamab-for-fda-approval/

News/ News/ Oncology

Genprex cancer gene therapy paired with AZ, Merck lung cancer drugs

Phil Taylor AstraZeneca, Genprex, immuno-oncology, Keytruda, Merck & Co, Non-small cell lung cancer, Oncology, Tagrisso 0 Comment

An experimental gene therapy developed by Texas biotech Genprex will be paired with AstraZeneca’s Tagrisso and Merck &

Genprex cancer gene therapy paired with AZ, Merck lung cancer drugs

https://pharmaphorum.com/news/genprex-cancer-gene-therapy-paired-with-az-merck-lung-cancer-drugs/

News/ News/ Oncology

FDA grants fast review for AstraZeneca’s Tagrisso in early-stage lung cancer

Richard Staines AstraZeneca, cancer, lung cancer, Non-small cell lung cancer, Tagrisso 0 Comment

The FDA has granted a fast review for AstraZeneca’s Tagrisso oncology drug in certain patients with early-stage lung

FDA grants fast review for AstraZeneca’s Tagrisso in early-stage lung cancer

https://pharmaphorum.com/news/fda-grants-fast-review-for-astrazenecas-tagrisso-in-early-stage-lung-cancer/

Market Access/ News/ News

Price cut wins NICE OK for AZ’s Tagrisso in untreated lung cancer

Phil Taylor AstraZeneca, NHS, NICE, Non-small cell lung cancer, Tagrisso 0 Comment

UK cost-effectiveness watchdog NICE has changed its stance on AstraZeneca’s Tagrisso as a first-line therapy for non-small cell

Price cut wins NICE OK for AZ’s Tagrisso in untreated lung cancer

https://pharmaphorum.com/news/price-cut-wins-nice-ok-for-azs-tagrisso-in-untreated-lung-cancer/

Trending

Tagrisso

Login